The short version of lyophilization fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-12-23 and is reviewed periodically as new material appears.
Material sold for research use varies widely in documented quality. A useful verification package includes a certificate of analysis that states peptide content rather than only net weight, the chromatographic method and column used, and a mass spectrum consistent with the expected mass. Independent testing by a third-party laboratory is occasionally reported. Statements of identity resting only on a supplier label provide little assurance, and the gap between nominal mass and actual peptide content can be substantial once counterions and residual water are counted.
Peptides of this size are generally stable as dry solids but degrade in solution over time. The principal routes are hydrolysis of the peptide backbone and oxidation, with hydrolysis favoured by elevated temperature and extreme pH. Aqueous solutions held at room temperature can show measurable loss of purity within days, while frozen aliquots are considerably more durable. Because the sequence contains neither cysteine nor methionine, oxidation is less of a concern than for many other peptides, but pH control during handling still matters.
Chemically, the molecule consists of four amino acid residues joined by three peptide bonds, with a free N-terminal amino group and a free C-terminal carboxyl group. Its molecular formula is C14H22N4O9, and its monoisotopic mass is approximately 390 daltons. The acidic glutamate and aspartate side chains give the peptide a net negative charge near neutral pH, a property that shapes its chromatographic behaviour and solubility profile. No disulfide bridges or other post-translational modifications are present, so the primary sequence alone defines the structure.
Most experimental work has been carried out in cell culture and animal models. Several reports describe changes in telomerase activity and proliferation in cultured cells, while rodent studies have examined lifespan, melatonin rhythm and reproductive endpoints. Human data remain limited, and much of the published clinical material consists of small trials with incomplete reporting of methods and controls. Whether the cell and animal findings translate into measurable effects in people is an open question, and the mechanistic basis of the reported telomerase changes is not fully established.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Freely soluble in water | Also dissolves in polar organic solvents |
| Typical storage temperature | −20 °C or below | Sealed, desiccated, protected from light |
| Primary purity assay | Reversed-phase HPLC | Ultraviolet detection near 214 nm |
| Identity confirmation | Mass spectrometry | Electrospray ionization commonly used |
Purity assessment of peptide reagents normally relies on reversed-phase high-performance liquid chromatography. A gradient of acetonitrile in water with trifluoroacetic acid, paired with a C18 stationary phase, separates the target tetrapeptide from truncated sequences and deletion analogues. Detection at 214 nanometres exploits absorbance of the peptide backbone, since the molecule contains no aromatic residue. Results are expressed as a percentage of total peak area. Values above ninety-five percent are typical for research-grade material, although reporting conventions vary between suppliers.
Identity confirmation uses mass spectrometry, usually electrospray ionisation in positive mode or matrix-assisted laser desorption. The protonated free peptide produces a signal near three hundred and ninety-one daltons, while salt adducts shift that value slightly. Tandem mass spectrometry or amino acid analysis supplies sequence-level confirmation, which a single mass measurement cannot. Peptides containing aspartate can cyclise into succinimide intermediates that hydrolyse to isoaspartate isomers of identical mass. Because those isomers are difficult to separate chromatographically, identity and purity results carry more weight when interpreted together.
Storage practice centres on limiting moisture, oxygen, and repeated temperature cycling. Freeze-dried powder is generally held desiccated at minus twenty degrees Celsius or colder and protected from light. Reconstituted solutions are markedly less stable, and the aspartate-glycine junction is prone to succinimide formation at neutral to mildly alkaline pH. Portioning material into single-use aliquots reduces degradation compared with repeated freeze-thaw cycles. Stability data specific to this tetrapeptide remain scarce, so most handling guidance is extrapolated from general peptide chemistry rather than measured directly.
Epitalon is a synthetic tetrapeptide with the residue sequence alanine-glutamate-aspartate-glycine, commonly abbreviated AEDG. Its monoisotopic mass is approximately 390.35 daltons, and it is usually supplied as a lyophilised trifluoroacetate or acetate salt. The compound was derived from a pineal gland extract called epithalamin, a heterogeneous preparation investigated in the former Soviet Union. Researchers associated with the Saint Petersburg Institute of Bioregulation and Gerontology described the tetrapeptide as a constituent fragment of that extract. Commercial material is offered as a laboratory reagent rather than as a finished pharmaceutical product.
Literature searches for this compound must account for several spelling variants. Indexing databases contain epitalon, epithalon, epithalone, and AEDG, and relevant records are scattered across Russian-language and English-language journals that do not consistently cross-cite. Early publications describe the parent extract as a mixture of many peptides, whereas later work addresses the single synthetic tetrapeptide. That shift in nomenclature complicates comparison between studies, because extract data and tetrapeptide data are sometimes cited interchangeably. A search strategy omitting the alternate spellings will return an incomplete set of references.
Reported biological findings come mainly from cell culture and rodent experiments. Those studies describe changes in telomerase catalytic subunit expression, melatonin rhythm amplitude, and antioxidant enzyme activity after peptide exposure. Human data are sparse and consist of small trials with limited blinding and inconsistent endpoints. The proposed mechanisms remain hypotheses rather than established facts, and there is no consensus on whether effects observed in animals carry over to people. Independent replication outside the original research groups is limited, which is a recognised gap in the published literature.
=== Neurotransmitters === The neurotransmitters that are most strongly associated with catatonia are GABA, dopamine, and glutamate. GABA is the primary inhibitory neurotransmitter of the brain, meaning it slows down the activity of the systems it acts on. In catatonia, people have low levels of GABA, which causes them to be overly activated, especially in areas of the brain that normally inhibit activity. This is thought to cause the behavioral symptoms associated with catatonia, including withdrawal. Dopamine can increase or decrease the activity of the area of the brain it acts on, depending on where in the brain it is. Dopamine is lower than normal in people with catatonia, which is thought to cause many of the motor symptoms, because dopamine is the main neurotransmitter that activates the parts of the brain responsible for movement. Glutamate is an excitatory neurotransmitter, meaning that it increases the activity of the areas of the brain it acts on. Notably, glutamate tells the neuron it acts on to fire by binding to the NMDA receptor. People with anti-NMDA receptor encephalitis can develop catatonia because their antibodies attack the NMDA receptor, reducing the brain's ability to activate different areas through glutamate.
=== Republic of Egypt (from 1953) === King Hussein of Jordan, 1955 Marshal Josip Broz Tito, President of the Federal People's Republic of Yugoslavia, 1956 Prof. Amintore Fanfani, Prime Minister and ad-interim Minister of Foreign Affairs of the Republic of Italy, 1959 Yuri Gagarin, Soviet cosmonaut, 1961 Taha Hussein, Egyptian writer, 1965 Umm kulthum, Egyptian singer and actress, 1965 Mohammed Abdel Wahab, Egyptian singer and composer, 1965 President Jimmy Carter, President of the United States, 1979 Emperor Akihito of Japan Emperor Amha Selassie of Ethiopia Mohammed Burhanuddin, 52nd Da'i al-Mutlaq of the Dawoodi Bohra, 1978 King Bhumibol Adulyadej of Thailand Mohamed ElBaradei, former director general of the International Atomic Energy Agency (IAEA) Queen Elizabeth II, 1975 Birendra Bir Bikram shah Dev, King of Nepal, 1974 Mohammad Reza Pahlavi, Shah of Iran, 1975 Hassaballah El Kafrawy, Egyptian former Minister of Housing Pengiran Anak Haji Mohamed Yusof, prince consort and cheteria of Brunei, 1984 Naguib Mahfouz, Egyptian writer, 1988 King Fahd bin Abdulaziz Al Saud of Saudi Arabia, 1989 Pierre Gemayel, founder of the Lebanese Phalange Emperor Haile Selassie of Ethiopia King Hamad bin Isa Al Khalifa of Bahrain, 2016 King Idris of Libya (Grand Cordon) Ekmeleddin İhsanoğlu, Turkish academic, diplomat and former Secretary-General of the Organisation of Islamic Cooperation (OIC) Émile Lahoud, President of Lebanon, 2000 Makarios III, former president of Cyprus Nelson Mandela, President of South Africa Adly Mansour, former Chief Justice of the Supreme Constitutional Court and former acting President of Egypt King Mohammed VI of Morocco Muhammad Naguib, First President of Egypt Nursultan Nazarbayev, President of Kazakhstan Antonín Novotný, President of Czechoslovakia Sultan Qaboos bin Said al Said of Oman, 1976 Ziaur Rahman, President of Bangladesh Heinrich Rau, East German politician (Grand Cordon), 1961 King Saud bin Abdulaziz Al Saud of Saudi Arabia, 1954 King Norodom Sihanouk of Cambodia William E. Simon, U.S. Secretary of the Treasury Suharto, President of Indonesia Field Marshal Mohamed Hussein Tantawi, former chairman of the Supreme Council of the Armed Forces of Egypt, 2012 Walter Ulbricht, President of East Germany, 1965 George Vasiliou, former president of Cyprus Sir Magdi Habib Yacoub, Egyptian professor of Cardiothoracic Surgery Professor Ahmed Zewail, Egyptian scientist Katerina Sakellaropoulou, President of Greece, 2020 Salva Kiir Mayardit, President of South Sudan, 2020 Haitham bin Tariq, Sultan of Oman, 2023 Narendra Modi, Prime Minister of India, 2023 Mufaddal Saifuddin, 53rd Da'i al-Mutlaq of the Dawoodi Bohras, 2023 Mishal Al-Ahmad Al-Jaber Al-Sabah, Emir of Kuwait, 2024 King Frederik X, King of Denmark, 2024 King Felipe VI, King of Spain, 2025 Donald Trump, President of the United States, 2025
=== Phrixotoxin-1 === Mice that are injected with phrixotoxin-1 can experience numerous, transient, adverse cardiac reactions, such as premature ventricular beats, ventricular tachycardia, and atrio-ventricular blocks. Neurological effects observed are motor impairment and convulsions. These effects are seen following both intravenous and intracisternal injection, making it likely that phrixotoxin-1 crosses the blood brain barrier (Diochot 1999).
In 1873, two years after the unification of Germany, Franz Joseph entered into the League of Three Emperors (Dreikaiserbund) with Emperor Wilhelm I of Germany and Emperor Alexander II of Russia, who was succeeded by Tsar Alexander III in 1881. The league had been designed by the German chancellor Otto von Bismarck, as an attempt to maintain the peace of Europe. It would last intermittently until 1887.
Sources: en.wikipedia.org
=== Progression free survival === The Progression Free Survival is usually used in analysing the results of the treatment for the advanced disease. The event for the progression free survival is that the disease gets worse or progresses, or the patient dies from any cause. Time to Progression is a similar endpoint that ignores patients who die before the disease progresses.
=== Signal transduction === GHRH binding to GHRHR results in increased GH production mainly by the cAMP-dependent pathway, but also by the phospholipase C pathway (IP3/DAG pathway), and other minor pathways. The cAMP-dependent pathway is initiated by the binding of GHRH to its receptor, causing receptor conformation that activates Gs alpha subunit of the closely associated G-Protein complex on the intracellular side. This results in stimulation of membrane-bound adenylyl cyclase and increased intracellular cyclic adenosine monophosphate (cAMP). cAMP binds to and activates the regulatory subunits of protein kinase A (PKA), allowing the free catalytic subunits to translocate to the nucleus and phosphorylate the transcription factor cAMP response element-binding protein (CREB). Phosphorylated CREB, together with its coactivators, p300 and CREB-binding protein (CBP) enhances the transcription of GH by binding to CREs cAMP-response elements in the promoter region of the GH gene. It also increases transcription of the GHRHR gene, providing positive feedback. In the phospholipase C pathway, GHRH stimulates phospholipase C (PLC) through the βγ-complex of heterotrimeric G-proteins. PLC activation produces both diacylglycerol (DAG) and inositol triphosphate (IP3), the latter leading to release of intracellular Ca2+ from the endoplasmic reticulum, increasing cytosolic Ca2+ concentration, resulting in vesicle fusion and release of secretory vesicles containing premade growth hormone.
This causes the inhibition of pro-inflammatory and pruritogenic (itch-causing) cytokines that depend on JAK1 and JAK3, which include IL-2, IL-4, IL-6, IL-13, and IL-31 (TSLP, another pruritogenic cytokine that uses JAKs, has also been found to be inhibited). IL-31 is a key cytokine at the pruritogenic receptors at neurons near the skin, and also induces peripheral blood mononuclear cells and keratinocytes to release pro-inflammatory cytokines. Suppression of IL-4 and IL-13 causes a decrease of Th2-cell differentiation, which plays a role in atopic dermatitis. Oclacitinib's relatively little effect on JAK2 prevent it from suppressing hematopoiesis or the innate immune response. Oclacitinib inhibits JAK, not the pruritogenic cytokines themselves; studies in mice showed that suddenly stopping the medication caused an increase in itchiness caused by a rebound effect, where more cytokines were produced to overcome lack of response by JAK.
Sources: en.wikipedia.org
The powder is normally kept at −20 °C or below in a sealed, moisture-protected container. Letting the vial reach room temperature before opening helps prevent condensation on the contents.
Reversed-phase HPLC with ultraviolet detection is the usual approach, often paired with mass spectrometry. Together the two methods address both chromatographic purity and molecular identity.
Differences arise from the analytical method, the detection wavelength, and whether the number refers to the peptide or to total powder mass. Counterion and water content can lower the actual peptide fraction considerably.
It is a synthetic tetrapeptide with the sequence alanine-glutamate-aspartate-glycine, often abbreviated AEDG. The molecule is linear and contains no modified residues, so it is fully described by its sequence.